IN2015DN00337A - - Google Patents

Info

Publication number
IN2015DN00337A
IN2015DN00337A IN337DEN2015A IN2015DN00337A IN 2015DN00337 A IN2015DN00337 A IN 2015DN00337A IN 337DEN2015 A IN337DEN2015 A IN 337DEN2015A IN 2015DN00337 A IN2015DN00337 A IN 2015DN00337A
Authority
IN
India
Prior art keywords
disorders
formula
tautomers
prodrugs
oxides
Prior art date
Application number
Other languages
English (en)
Inventor
Hervé Geneste
Michael Ochse
Karla Drescher
Clarissa Jakob
Original Assignee
Abbvie Deutschland
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48986145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00337(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland
Publication of IN2015DN00337A publication Critical patent/IN2015DN00337A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN337DEN2015 2012-08-17 2013-08-16 IN2015DN00337A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684290P 2012-08-17 2012-08-17
PCT/EP2013/067122 WO2014027078A1 (en) 2012-08-17 2013-08-16 Inhibitor compounds of phosphodiesterase type 10a

Publications (1)

Publication Number Publication Date
IN2015DN00337A true IN2015DN00337A (zh) 2015-06-12

Family

ID=48986145

Family Applications (1)

Application Number Title Priority Date Filing Date
IN337DEN2015 IN2015DN00337A (zh) 2012-08-17 2013-08-16

Country Status (24)

Country Link
US (1) US9464085B2 (zh)
EP (1) EP2885299B1 (zh)
JP (1) JP2015524833A (zh)
KR (1) KR20150042798A (zh)
CN (1) CN104684912A (zh)
AR (1) AR092167A1 (zh)
AU (1) AU2013304043A1 (zh)
BR (1) BR112015003236A2 (zh)
CA (1) CA2879485A1 (zh)
CL (1) CL2015000370A1 (zh)
CR (1) CR20150082A (zh)
DO (1) DOP2015000029A (zh)
EC (1) ECSP15010205A (zh)
HK (1) HK1211284A1 (zh)
IL (1) IL236946A0 (zh)
IN (1) IN2015DN00337A (zh)
MX (1) MX2015002000A (zh)
PE (1) PE20151069A1 (zh)
PH (1) PH12015500348A1 (zh)
RU (1) RU2015109135A (zh)
SG (1) SG11201501111YA (zh)
TW (1) TW201412742A (zh)
UY (1) UY34980A (zh)
WO (1) WO2014027078A1 (zh)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030166476A1 (en) 2002-01-31 2003-09-04 Winemiller Mark D. Lubricating oil compositions with improved friction properties
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
MXPA06014236A (es) 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
CA2619462A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
JP2009524637A (ja) 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
AU2007217750A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009527562A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
JP2009527542A (ja) 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
CA2643044A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
WO2008006372A1 (en) 2006-07-10 2008-01-17 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090062291A1 (en) 2007-08-22 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
AU2008329072A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
CA2706866A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2011008597A1 (en) 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
TW201204727A (en) 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
DE102010025786A1 (de) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline

Also Published As

Publication number Publication date
UY34980A (es) 2014-03-31
BR112015003236A2 (pt) 2017-07-04
IL236946A0 (en) 2015-03-31
HK1211284A1 (zh) 2016-05-20
AR092167A1 (es) 2015-03-25
MX2015002000A (es) 2015-10-09
US20140051695A1 (en) 2014-02-20
EP2885299B1 (en) 2017-04-05
DOP2015000029A (es) 2015-03-15
CN104684912A (zh) 2015-06-03
AU2013304043A1 (en) 2015-02-05
KR20150042798A (ko) 2015-04-21
US9464085B2 (en) 2016-10-11
ECSP15010205A (es) 2016-01-29
RU2015109135A (ru) 2016-10-10
JP2015524833A (ja) 2015-08-27
CR20150082A (es) 2015-05-25
CL2015000370A1 (es) 2015-10-02
WO2014027078A1 (en) 2014-02-20
PE20151069A1 (es) 2015-08-29
PH12015500348A1 (en) 2015-04-20
TW201412742A (zh) 2014-04-01
SG11201501111YA (en) 2015-03-30
CA2879485A1 (en) 2014-02-20
EP2885299A1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
MX2015012008A (es) Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
PH12015501962A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MX2012012952A (es) Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina.
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK1138262A1 (en) Novel phosphodiesterase inhibitors
TW200730506A (en) Compounds and uses thereof
MX355142B (es) Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor).
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
MY167396A (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2008155572A3 (en) Fused quinoline derivatives useful as gaba modulators
IN2015DN00957A (zh)
HK1164721A1 (en) Therapeutic uses of quinazolinedione derivatives
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MY193754A (en) Treatment for parkinson's disease
MX2015003419A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.
IN2014DN09826A (zh)
IN2015DN00337A (zh)
MX2015006539A (es) Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
NZ624124A (en) Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
TH127359B (th) อนุพันธ์ 1,2,4-ไตรอะโซโล[4,3-a]ไพริดีนและการใช้มันในฐานะโพสิทิฟ อัลโลสเตริก มอดูเลเตอร์ ของหน่วยรับความรู้สึก MGLUR2